New tablet production facility in Ingelheim: Centerpiece for global launches

Boehringer IngelheimBoehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches. The research-driven pharmaceutical company is therefore investing 85 million euros in Ingelheim, focusing on modern and flexible production, to be even better positioned for marketing new, innovative drugs.

Starting in 2020, 75 employees will develop new production methods for tablet preparations and manufacture these centrally for all global market launches. In return, the production of older, easier-to-manufacture drugs has been gradually relocated to different countries in the worldwide manufacturing network since 2016, allowing greater focus on the more demanding tasks of chemical production. The Solids Launch facility is an important piece of the puzzle, allowing Boehringer Ingelheim to keep the entire value-added chain in Germany over the long term, from research right through to production.

"In Ingelheim, we are thoroughly committed to investing in technologies and processes with high added value. This means that we are not only establishing the centerpiece for global market launches of pharmaceutical innovations here, but also that we will continue to manufacture drugs that require highly complex production technologies," explained Stefan Rinn, Country Manager for Germany.

Malu Dreyer, Minister President of Rhineland-Palatinate, underscored the importance of future-oriented technologies that significantly add value for the region as a business hub. On the occasion of the groundbreaking ceremony, she thanked Boehringer Ingelheim for its commitment to doing business in Rhineland-Palatinate, where Boehringer Ingelheim is an icon of progress, innovation, and sustainable development. The company creates valuable jobs and training positions. "Here, smart people are making exceptional contributions to improving the health and quality of life of patients. The chemical and pharmaceutical industry generates the highest turnover in Rhineland-Palatinate and is therefore an important engine for growth."

The state supports companies, among other things, with measures to ensure specialist staff. The "oval table," unique to this regional state government, involves chambers of trade and business associations to implement a strategy that is backed by professionals and strengthened through apprenticeships. Furthermore, the region wants to get more children and young people excited about science, technology, engineering, and mathematics through its STEM initiative. "Our children are the researchers of tomorrow," says Minister President Dreyer.

Between 2016 and 2017, Boehringer Ingelheim constructed a production facility in Ingelheim in record time, at a cost of 34 million euros - known as the "diabetes factory," for innovative antidiabetic agents. As of 2020, the production of such preparations is to be relocated to other countries, such as Mexico and Greece. The facility was designed for flexibility and serves as a part of the new production strategy to prepare for product launches as well as be able to react promptly to market changes and develop products internally.

Country Manager Stefan Rinn continued, "Germany will continue to be by far the largest production site in the Boehringer Ingelheim group of companies, and Ingelheim will remain one of the largest production sites in the world within the pharmaceutical industry as a whole."

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Bayer inks deals with eleven startups under G4A Di…

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup c...

Akcea and Pfizer Inc. announce licensing agreement…

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the com...